一周内,强生连续叫停两款新药研发项目!

中国制药网
12 Mar

近年来,有诸多药企叫停了研发管线,叫停在研管线多的企业一年内就达12条。2025年以来,又有多款重磅新药研发被终止。其中, 强生 因疗效不足,终止在研药物aticaprant用于治疗重度抑郁症(MDD)的3期项目后,不到一周又宣布了放弃新一代CD38单抗选择权。3月10日消息,强生公司(J&J)宣布放弃对新一代CD38单抗HexaBody-CD38(GEN3014)全球许可开发、生产和商业化的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10